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Objectives: A new inhaled antimicrobial (levoﬂoxacin nebulizer solution; APT-
1026) was studied prospectively to assess its utility in managing patients with
chronic Pseudomonas aeruginosa (PA) lung infection.
Methods: This was a non-randomized, single-arm 24-wk Extension to a ran-
domized, open-label Phase 3 study (MPEX-209) comparing APT-1026 (240mg
BID) with tobramycin nebulization solution (TNS; 300mg BID) over three 28-day
on/28-day off cycles in CF patients with chronic PA lung infection. Patients either
continued cyclic treatment with APT-1026 or switched from TNS to APT-1026
following prior cyclic TNS for 3 additional cycles. Efﬁcacy endpoints included
spirometry and CFQ-R respiratory domain; safety was assessed at 28-day intervals.
Results: 88 patients enrolled in the Extension to receive APT-1026 for three
additional cycles (56 continuing APT-1026; 32 switched from TNS). In 47 patients
completing 6 cycles of APT-1026, FEV1 % predicted increased similarly in Cycles
1−3 of MPEX-209 and Cycles 4−5 of the Extension, with lesser response at Cycle
6. Most (72 to 79%) patients switched from TNS to APT-1026 improved FEV1
above their post-TNS baselines during Cycles 4−6. Patients switched from TNS
to APT-1026 also experienced symptomatic beneﬁt assessed by CFQ-R during the
Extension, resembling patients originally receiving APT-1026. APT-1026 was well-
tolerated and no new signiﬁcant AEs were identiﬁed during the Extension. Adverse
events led to early Extension discontinuation in 4 patients.
Conclusion: This Extension study contributes to evidence that APT-1026 240mg
BID is safe and effective for long-term management of chronic lung infection due
to PA.
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Objectives: To evaluate how inhaled antibiotic (iABX) management of patients (pts)
seen at The Cleveland Adult CF Center was affected by introduction of aztreonam
for inhalation solution (Az).
Methods: Treatment records for pts receiving inhaled colistin (Co), an inhaled
aminoglycoside (Ag), or Az at 1 encounter from 2009–2012 were obtained from
the local Port CF Patient Registry. Annual iABX use and regimens (month on/month
off, continuous, or other) were compared.
Results: 172 pts were studied; 127 in 2009, 118 in 2010, and 130 in 2011 and 2012.
From 2009–2012, the prevalence of Co and Ag use at any encounter (independent
of regimen) decreased (56% to 41% and 74% to 62%, respectively) while Az
prevalence increased from 3% to 50%. Overall prevalence of month-on/month-off
or continuous iABX use did not change over the period. However, the prevalence of
patients alternating iABX (Co/Ag, Co/Az, or Az/Ag) increased from 20% in 2009
to 39% in 2012. The prevalence of patients that used 2 classes of iABX at any
point in the year (not necessarily in alternating regimens) increased from 28% in
2009 to 45% in 2012.
Conclusion: At the Cleveland Adult CF Center, introduction of Az in 2010 did not
coincide with a change in the prevalence of patients using month on/month off or
continuous iABX regimens, although the prevalence of individual iABX class use
did change. In contrast, Az introduction did lead to a substantial increase in the
prevalence of patients reported to be receiving multiple iABX classes during the
year. The increasing prevalence of multiple iABX use has important implications
for the design of future iABX studies, patient care, and evaluation of treatment
burden.
